HealthTree Logo
search more_vert
close
person Sign In / Create Account
Miami Myeloma Roundtable
Miami Myeloma Roundtable image
HealthTree Roundtables for Multiple Myeloma
Can't make it to the event?
Sign up and receive the event recording by email

Event Description

Join us for the Miami Myeloma Round Table at the Hilton Fort Lauderdale Marina, April 20th from 9:00 am-2:30 pm ET to hear from top myeloma researchers as they share their expertise with patients and caregivers. The day includes informative and engaging presentations about the latest in myeloma as well as breakout sessions for both newly diagnosed and relapsed/refractory patients. The event will feature two sessions that include extensive Q&A. Registration and breakfast opens at 8:00 am.

MEETING DETAILS

  • Meeting date: Saturday, April 20th, 2024
  • Registration and breakfast begins at 8:00 am, meeting begins at 9:00 am
  • Location: Hilton Fort Lauderdale Marina, 1881 SE 17th Street Ft. Lauderdale, FL 33316
  • Registration, parking, breakfast and lunch are free
  • The meeting will be recorded and available to watch at a later time
  • Nearest Airport: Fort Lauderdale-Hollywood International Airport (FLL)

REGISTRATION TO WATCH THE RECORDING

If you can't make the meeting in person, please register to watch the recording. We will send an email out to all recording registrants about a week following the live meeting.

MAKE IT A WEEKEND:

If you are traveling to the meeting and would like to make a weekend of it while you are in Fort Lauderdale, here are some suggestions:

QUESTIONS?

For questions about registration, contact us at +1-800-709-1113 or support@healthtree.org.

For all other questions, contact Elisabeth at +1-801-864-5073 or elisabeth@healthtree.org.

 

*Si hablas español y te gustaría tener traducción en vivo durante el evento, por favor escríbe a elisabeth@healthtree.org. 

 

Special thanks to our program sponsors

 

Schedule & Agenda

person
Registration
8:00 AM
  • Full breakfast and registration
The panelist Jennifer Ahlstrom
Welcome
9:00 AM
Jennifer Ahlstrom
  • Welcome and Introduction to HealthTree
The panelist David Coffey, M.D.
The Emerging World of Bispecific Antibodies
9:15 AM
David Coffey, M.D.
  • How they work and for whom
  • Continuous or fixed duration treatment
  • Side effect management
  • In or outpatient experiences
  • Use in earlier lines of therapy
The panelist Damian Green, MD
The History and Promise of CAR T
9:45 AM
Damian Green, MD
  • CAR T's innovative history
  • Who should and shouldn't consider CAR T
  • Earlier uses: newly diagnosed patients or at first relapse
  • The practicalities of access
  • Emerging CAR T innovations
person
Break
10:15 AM
The panelist C. Ola Landgren, MD, PhD
Blood-Based MRD Tracking
10:30 AM
C. Ola Landgren, MD, PhD
  • The utility of MRD testing
  • Types of blood-based tests with pros and cons
  • How MRD can change clinical trial end points
The panelist Jennifer Ahlstrom
HealthTree Cure Hub
11:00 AM
Jennifer Ahlstrom
person
Breakout Session
11:15 AM

C. Ola Landgren, MD, PhD - Newly Diagnosed Multiple Myeloma (NDMM) Breakout Session: Optimizing Treatment for Newly Diagnosed Myleoma Patients

OR

Benjamin Diamond, MD - Relapsed/Refractory Multiple Myeloma (RRMM) Breakout Session: Modernized Myeloma Care in the Age of Immunotherapy

person
Lunch
12:00 PM
The panelist Benjamin Diamond, MD
Precision Medicine in Myeloma
1:00 PM
Benjamin Diamond, MD
  • Using genetics to define risk
  • Computerized models to help determine optimal care
  • Genetics + immune system status - looking at the whole picture
  • How RWD can help
person
Faculty Q&A
1:30 PM
  • Faculty will answer questions from the audience
person
Help with HealthTree
2:15 PM
  • Meet the HealthTree team
  • Get educated with HealthTree programs
  • Raffle at 2:15 pm

Speakers & Moderators

The panelist C. Ola Landgren, MD, PhD
C. Ola Landgren, MD, PhD

C. Ola Landgren, MD, PhD, is Professor of Medicine, Chief of the Myeloma Program, and Leader of the Experimental Program at the University of Miami Sylvester Cancer Center. Read more about his move to Miami here. Dr. Landgren is a pioneer in the drug development and minimal residual disease (MRD) testing in myeloma. In collaboration with colleagues throughout the world, he develops new strategies (including cell-based, molecular-based, and imaging-based) and continues to be a leader of using advanced MRD testing in clinical trials. He is involved in the service’s rational treatment program (small molecule, monoclonal antibody, immune-based) for newly diagnosed, relapsed and refractory myeloma and amyloidosis patients. His research focuses on early drug development, advanced disease monitoring by new minimal residual disease (MRD) assays and biomarkers, and immune-PET to monitor treatment. He also studies mechanism and markers of progression from MGUS/smoldering myeloma to symptomatic multiple myeloma, and the identification of high-risk precursor patients who may be candidates for early treatment. Prior to joining Miami, Dr. Landgren was the Chief Attending Physician of the Myeloma Service at Memorial Sloan Kettering and Professor of Medicine at the Weill Cornell Medical College in New York City and Chief of the Multiple Myeloma Section of the National Cancer Institute in Bethesda, MD. Dr. Landgren received his MD at Karolinska Institute in Stockholm, Sweden; and he has had fellowships at Karolinska University Hospital and the National Cancer Institute. He is a frequent speaker at national and international meetings, and has published more than 400 peer-reviewed papers.

Read Bio
The panelist Benjamin Diamond, MD
Benjamin Diamond, MD

Dr. Diamond is a hematologist/oncologist who specializes in the treatment of plasma cell disorders including monoclonal gammopathy of undetermined significance, smoldering myeloma, and multiple myeloma. His research interests include utilization of minimal residual disease (MRD)-guided approaches to clinical decision-making, maintenance therapy, and the genomics of multiple myeloma and secondary malignancies that occur in patients treated for multiple myeloma. He completed fellowship at Memorial Sloan Kettering Cancer Center, spending a year as chief fellow, and has just recently joined the myeloma group at Sylvester Comprehensive Cancer Center where he is now a member of the Myeloma Genomics Laboratory participating in translational research. Some of his current projects include: Characterizing the genomics and origin of therapy-related myelodysplastic syndromes and acute leukemias that develop post-melphalan treatment. An investigation of commonalities between rare structural variants seen in multiple myeloma at diagnosis and relapse; including real world data collected by HealthTree.

Read Bio
The panelist David Coffey, M.D.
David Coffey, M.D.

David Coffey, M.D. is a physician-scientist at the Sylvester Comprehensive Cancer Center and the University of Miami. As a medical oncologist, he specializes in treating patients with multiple myeloma. His research is focused on understanding the interactions between myeloma tumor cells and the immune system. Leveraging his skills in computational biology, Dr. Coffey has developed analytical techniques to investigate the cells within the tumor microenvironment using single-cell gene expression profiling and DNA sequencing. He aims to understand how the immune system may fail to prevent myeloma progression and learn new ways to harness the immune system’s power to eliminate the disease more effectively.

Read Bio
The panelist Damian Green, MD
Damian Green, MD

Dr. Damian Green develops new immunotherapies that harness the power of the immune system to treat and ultimately eradicate multiple myeloma and lymphoma. A major research focus is radioimmunotherapy, in which radioactive particles are linked to cancer-targeting molecules called antibodies to deliver deadly radiation straight to cancer cells while sparing healthy tissues. Dr. Green also studies a type of immunotherapy called bispecific antibody therapy in which a two-pronged antibody brings together cancer-killing immune cells and cancer cells. Another major focus of his work is the development and clinical evaluation of a form of genetically engineered T-cell therapy (called CAR T-cell therapy) for patients with myeloma.

Read Bio
The panelist Jennifer Ahlstrom
Jennifer Ahlstrom

Myeloma survivor, patient advocate, wife, mom of 6. Believer that patients can help accelerate a cure by weighing in and participating in clinical research. Founder of the HealthTree Foundation.

Read Bio

Have Any Questions?

Thank you for your interest in the event. If you have any questions, we would love to help!

Feel free to give us a call or send us a message below.

support

Get In Touch With Us

phone

1-800-709-1113

email

Support@healthtree.org

Get the latest thought leadership on Multiple Myeloma delivered straight to your inbox.

Subscribe to the weekly "HealthTree Community for Multiple Myeloma Newsletter" for Multiple Myeloma news, life with Multiple Myeloma stories, Multiple Myeloma clinical trials, Multiple Myeloma 101 articles and events with Multiple Myeloma experts.

Thanks to our HealthTree Community for Multiple Myeloma Sponsors:

Johnson and Johnson
Sanofi
GSK
Regeneron
Bristol Myers Squibb

Follow Us

facebook instagram linkedin tiktok youtube